We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body'... Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany. Show more
The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR wild-type non-small cell lung cancer have been...
AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer (NSCLC) EGFR-wildtype cohort: one complete...
MANNHEIM, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
MANNHEIM, Germany, March 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Data update from AFM24-102 Phase 1/2a combination study includes 15 heavily pre-treated patients from the EGFR-wildtype (wt) non-small cell lung cancer (NSCLC) expansion cohortFollow-up shows...
Dr. Adi Hoess to step down as CEO and Management Board MemberDr. Andreas Harstrick appointed Interim CEOStrategic restructuring reducing headcount by up to 50%, extending cash runway into H2...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.03 | -0.592885375494 | 5.06 | 5.46 | 4.56 | 63667 | 5.00266074 | CS |
4 | -0.35 | -6.50557620818 | 5.38 | 7.24 | 4.56 | 107992 | 6.01573326 | CS |
12 | -0.488 | -8.8437839797 | 5.518 | 7.24 | 4.245 | 389843 | 5.83051984 | CS |
26 | 1.53 | 43.7142857143 | 3.5 | 7.4 | 2.235 | 758963 | 5.00749185 | CS |
52 | -3.37 | -40.119047619 | 8.4 | 11.1 | 2.235 | 769407 | 5.75245915 | CS |
156 | -107.77 | -95.5407801418 | 112.8 | 117.4 | 2.235 | 1209206 | 34.53047812 | CS |
260 | -28.07 | -84.8036253776 | 33.1 | 117.4 | 2.235 | 1243944 | 42.13748539 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions